Interestingly, these somatostatin deficits were systematically more robust in female subjects across cohorts and regions (Sibille et al., 2011; Tripp et al., 2011, 2012; Guilloux et al., 2012), consistent with the female heightened vulnerability to develop MDD, and suggesting that low somatostatin may represent a molecular correlate of sexual dimorphism in vulnerability to affect dysregulation. The gene discussed is SST; the disease is major depressive disorder.